Studies on Anti-platelet Agents. IV. A Series of 2-Substituted 4,5-Bis(4-methoxyphenyl)pyrimidines as Novel Anti-platelet Agents.
作者:Akito TANAKA、Yukio MOTOYAMA、Hisashi TAKASUGI
DOI:10.1248/cpb.42.1828
日期:——
The syntheses and structure-activity relationships of a series of 2-substituted 4,5-bis(4-methoxyphenyl)pyrimidines, designed on the basis of structural analyses of several cyclooxygenase (CO) inhibitors, and their derivatives as anti-platelet agents based on CO inhibition are described. Among them, 4,5-bis(4-methoxyphenyl)-2-morpholinopyrimidine (8) and 4,5-bis(4-methoxyphenyl)-2-(3,5-dimethylmor
一系列2-取代的4,5-双(4-甲氧基苯基)嘧啶的合成与构效关系,是基于几种环加氧酶(CO)抑制剂及其衍生物作为抗血小板药的结构分析而设计的描述了对CO的抑制作用。其中,显示了4,5-双(4-甲氧基苯基)-2-吗啉代嘧啶(8)和4,5-双(4-甲氧基苯基)-2-(3,5-二甲基吗啉-4-基)嘧啶(9)对丙二醛的强抑制活性,这是通过前列腺素中花生四烯酸(AA)的CO催化氧合形成的,在体外产生(在10(-8)M和IC50 = 1.4 x 10(-8)M时分别抑制73.4%) 。在离体研究中还检查了某些化合物。这些化合物中,4,5-双(4-甲氧基苯基)-2-(1-甲基-1,2,3,6-四氢吡啶-4-基)嘧啶(11a)离体显示有效而持久的抗血小板活性,即11a在口服给予3.2 mg / kg的24小时后仍显示出由AA诱导的97%的血小板凝集抑制作用。豚鼠,低剂量(1.0 mg / kg)后6 h抑